BurTech Acquisitionの空売り状況は、投資家がBurTech Acquisitionの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

BurTech Acquisition (NASDAQ:BRKH) 株価情報, 空売り情報

BurTech Acquisition Corp is a blank check company.

BurTech Acquisition Corp. - Class A Common Stock

BurTech Acquisition Corp

<p><a href="https://truthsocial.com/@realDonaldTrump/113488754953884936" title="https://truthsocial.com/@realDonaldTrump/113488754953884936">https://truthsocial.com/@realDonaldTrump/113488754953884936</a></p>


News

Politics

General

President-elect Trump Nominates North Dakota Governor, Doug Burgum, To Join Administration As Secretary Of The Interior And As Chairman Of Newly Formed National Energy Council

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Baidu</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BIDU, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Baidu.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 70% bullish and 30%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $734,906, and 12 are calls, for a total amount of $564,254.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $120.0 for Baidu over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Baidu's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Baidu's significant trades, within a strike price range of $75.0 to $120.0, over the past month.</p>
<h3>Baidu 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700888_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$38.35</td>
<td>$38.0</td>
<td>$38.0</td>
<td>$120.00</td>
<td>$228.0K</td>
<td>376</td>
<td>60</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$75.00</td>
<td>$176.7K</td>
<td>5.8K</td>
<td>511</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.6</td>
<td>$16.35</td>
<td>$16.52</td>
<td>$100.00</td>
<td>$82.6K</td>
<td>2.5K</td>
<td>56</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.55</td>
<td>$2.53</td>
<td>$2.55</td>
<td>$90.00</td>
<td>$76.2K</td>
<td>3.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.55</td>
<td>$2.5</td>
<td>$2.51</td>
<td>$90.00</td>
<td>$75.2K</td>
<td>3.6K</td>
<td>715</td>
</tr>
</tbody>
</table>
</p>
<h3>About Baidu</h3>
<p>Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.</p>
<p>Following our analysis of the options activities associated with Baidu, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Baidu</h3>
<ul>
<li>Currently trading with a volume of 1,780,410, the BIDU's price is up by 0.47%, now at $84.45. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About Baidu</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $115.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Baidu, targeting a price of $115. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Baidu options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

BIDU

Check Out What Whales Are Doing With BIDU

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Albemarle</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALB, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Albemarle.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 33% bullish and 58%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $645,810, and 3 are calls, for a total amount of $127,222.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $110.0 for Albemarle during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Albemarle options trades today is 1266.0 with a total volume of 2,294.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Albemarle's big money trades within a strike price range of $95.0 to $110.0 over the last 30 days.</p>
<h3>Albemarle Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700884_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.85</td>
<td>$11.6</td>
<td>$11.65</td>
<td>$95.00</td>
<td>$291.2K</td>
<td>790</td>
<td align="right">250</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.95</td>
<td>$12.9</td>
<td>$12.9</td>
<td>$110.00</td>
<td>$101.9K</td>
<td>2.9K</td>
<td align="right">341</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$7.75</td>
<td>$7.6</td>
<td>$7.62</td>
<td>$100.00</td>
<td>$57.1K</td>
<td>1.4K</td>
<td align="right">219</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$13.0</td>
<td>$12.7</td>
<td>$12.85</td>
<td>$110.00</td>
<td>$43.6K</td>
<td>2.9K</td>
<td align="right">407</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.65</td>
<td>$13.55</td>
<td>$13.65</td>
<td>$110.00</td>
<td>$42.3K</td>
<td>2.9K</td>
<td align="right">81</td>
</tr>
</tbody>
</table>
</p>
<h3>About Albemarle</h3>
<p>Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.</p>
<p>Following our analysis of the options activities associated with Albemarle, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Albemarle Standing Right Now?</h3>
<ul>
<li>With a volume of 1,232,520, the price of ALB is down -0.61% at $101.48. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 89 days.</li>
</ul>
<h3>What The Experts Say On Albemarle</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $127.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Albemarle with a target price of $170.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Albemarle with a target price of $127.<br />
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Albemarle, targeting a price of $79.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Albemarle, which currently sits at a price target of $133. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Albemarle options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in Albemarle

<p>In the last three months, 10 analysts have published ratings on Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $120.3, a high estimate of $142.00, and a low estimate of $105.00. This upward trend is evident, with the current average reflecting a 11.39% increase from the previous average price target of $108.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700881_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Morgan Stanley among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$142.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$122.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$107.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$121.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Daniel Fannon</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$112.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Saul Martinez</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$118.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$105.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Morgan Stanley. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Morgan Stanley compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Morgan Stanley's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Morgan Stanley's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Morgan Stanley analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Morgan Stanley</h2>
<p>Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.</p>
<h3>A Deep Dive into Morgan Stanley's Financials</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Morgan Stanley's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>15.47%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Morgan Stanley's net margin excels beyond industry benchmarks, reaching <strong>21.12%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Morgan Stanley's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.26%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Morgan Stanley's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.25%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Morgan Stanley's debt-to-equity ratio surpasses industry norms, standing at <strong>3.37</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Beyond The Numbers: 10 Analysts Discuss Morgan Stanley Stock

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>BioNTech</strong>.</p>
<p>Looking at options history for BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 54% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $442,050 and 4, calls, for a total amount of $353,063.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $92.5 and $120.0 for BioNTech, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of BioNTech stands at 369.29, with a total volume reaching 2,574.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in BioNTech, situated within the strike price corridor from $92.5 to $120.0, throughout the last 30 days.</p>
<h3>BioNTech Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700878_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$23.6</td>
<td>$19.7</td>
<td>$23.6</td>
<td>$115.00</td>
<td>$160.4K</td>
<td align="right">140</td>
<td align="right">129</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.5</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$120.00</td>
<td>$105.9K</td>
<td align="right">108</td>
<td align="right">261</td>
</tr>
<tr>
<td>BNTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.6</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$105.00</td>
<td>$88.4K</td>
<td align="right">818</td>
<td align="right">429</td>
</tr>
<tr>
<td>BNTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$12.3</td>
<td>$11.5</td>
<td>$12.3</td>
<td>$110.00</td>
<td>$67.6K</td>
<td align="right">921</td>
<td align="right">55</td>
</tr>
<tr>
<td>BNTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$11.6</td>
<td>$11.3</td>
<td>$11.6</td>
<td>$110.00</td>
<td>$64.9K</td>
<td align="right">921</td>
<td align="right">489</td>
</tr>
</tbody>
</table>
</p>
<h3>About BioNTech</h3>
<p>BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.</p>
<h3>Current Position of BioNTech</h3>
<ul>
<li>With a volume of 2,881,741, the price of BNTX is down -3.1% at $100.35. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 124 days.</li>
</ul>
<h3>Expert Opinions on BioNTech</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $135.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan persists with their Neutral rating on BioNTech, maintaining a target price of $124.<br />
&#x2A; An analyst from Goldman Sachs has elevated its stance to Buy, setting a new price target at $137.<br />
&#x2A; An analyst from TD Cowen persists with their Hold rating on BioNTech, maintaining a target price of $122.<br />
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on BioNTech with a target price of $171.<br />
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Hold rating for BioNTech, targeting a price of $122. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest BioNTech options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


BNTX

BioNTech's Options: A Look at What the Big Money is Thinking

<p>In the preceding three months, 4 analysts have released ratings for Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $63.5, a high estimate of $75.00, and a low estimate of $49.00. This current average has not changed from the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700865_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Silence Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Silence Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Silence Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Silence Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Silence Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SLN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Silence Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Silence Therapeutics</h2>
<p>Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.</p>
<h3>Silence Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Silence Therapeutics faced challenges, resulting in a decline of approximately <strong>-93.43%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Silence Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-2602.34%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Silence Therapeutics's ROE excels beyond industry benchmarks, reaching <strong>-13.17%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Silence Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-8.13%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Silence Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.0</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 4 Ratings For Silence Therapeutics

Buybacks

FSBW

FS Bancorp Completes $5M Share Repurchase Program And Authorizes Additional $5M Buyback To Run Through October 2025

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.75, a high estimate of $22.00, and a low estimate of $21.00. Observing a 12.99% increase, the current average has risen from the previous average price target of $19.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700858_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Independence Realty Trust by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kim</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Derek Johnston</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Austin Wurschmidt</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Independence Realty Trust. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Independence Realty Trust compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Independence Realty Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Independence Realty Trust's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IRT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Independence Realty Trust analyst ratings.</strong></a></p>
<h2>About Independence Realty Trust</h2>
<p>Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.</p>
<h3>A Deep Dive into Independence Realty Trust's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Independence Realty Trust faced challenges, resulting in a decline of approximately <strong>-5.02%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>7.72%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Independence Realty Trust's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.37%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Independence Realty Trust's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.21%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.68</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Independence Realty Trust's Future

<p>TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) has been analyzed by 17 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for TJX Companies, presenting an average target of $132.18, a high estimate of $148.00, and a low estimate of $115.00. This upward trend is apparent, with the current average reflecting a 9.35% increase from the previous average price target of $120.88.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700848_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of TJX Companies among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$134.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$128.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$134.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$126.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TJX Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TJX Companies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for TJX Companies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into TJX Companies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TJX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on TJX Companies analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind TJX Companies</h2>
<p>TJX Companies is the leading off-price retailer of apparel, accessories, and home merchandise in the United States. The firm leverages its more than 21,000 global vendor relationships to procure and sell brand-name merchandise at prices 20%-60% cheaper than conventional retail channels. TJX opportunistically purchases excess inventory that stems from manufacturing overruns and retail closeout sales. The off-price retailer disperses its vast and disparate merchandise across its 5,000 global stores, creating a treasure-hunt shopping experience for consumers. Over three quarters of TJX's sales are derived from the United States, primarily via the T.J. Maxx, Marshalls, and HomeGoods banners. About 10% of sales are from Canada and 12% from Europe and Australia.</p>
<h3>TJX Companies: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> TJX Companies displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>5.57%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> TJX Companies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.16%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> TJX Companies's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>14.38%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> TJX Companies's ROA excels beyond industry benchmarks, reaching <strong>3.65%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> TJX Companies's debt-to-equity ratio surpasses industry norms, standing at <strong>1.63</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 17 Analyst Ratings For TJX Companies

<p>Throughout the last three months, 4 analysts have evaluated Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Nexxen International, revealing an average target of $9.5, a high estimate of $11.00, and a low estimate of $8.50. This upward trend is evident, with the current average reflecting a 22.58% increase from the previous average price target of $7.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700833_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Nexxen International by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.50</td>
<td>$8.50</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.50</td>
<td>$6.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nexxen International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nexxen International compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Nexxen International's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nexxen International's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NEXN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Nexxen International analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Nexxen International</h2>
<p>Nexxen International Ltd empowers advertisers, agencies, publishers, and broadcasters to utilize video and connected TV. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with advanced and exclusive data at its core.</p>
<h3>Nexxen International's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Nexxen International's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>19.0%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>3.29%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Nexxen International's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>0.56%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Nexxen International's ROA excels beyond industry benchmarks, reaching <strong>0.35%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Nexxen International's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.07</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NEXN

Demystifying Nexxen International: Insights From 4 Analyst Reviews

<p>Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $36.75, along with a high estimate of $41.00 and a low estimate of $33.00. Experiencing a 10.91% decline, the current average is now lower than the previous average price target of $41.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731700825_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Helmerich &amp; Payne among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$41.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Helmerich &amp; Payne. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Helmerich &amp; Payne compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Helmerich &amp; Payne's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Helmerich &amp; Payne's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Helmerich &amp; Payne analyst ratings.</strong></a></p>
<h2>About Helmerich &amp; Payne</h2>
<p>Helmerich &amp; Payne maintains one of the largest fleets of land drilling rigs in the US. The company's FlexRig line is the leading choice to drill horizontal wells for production of US tight oil and gas. H&amp;P is present in nearly every major US shale play and has a small but growing presence internationally.</p>
<h3>Helmerich &amp; Payne's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Challenges:</strong> Helmerich &amp; Payne's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-3.62%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Helmerich &amp; Payne's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>12.54%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Helmerich &amp; Payne's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.09%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.96%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.19</strong>, Helmerich &amp; Payne adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For Helmerich & Payne

<p><strong>Ark Invest </strong>CEO <strong>Cathie Wood </strong>has been a vocal bull for the cryptocurrency sector for years, specifically for leading cryptocurrency <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), which she recently said could be helped by the incoming <a href="https://www.benzinga.com/24/11/41928272/cathie-woods-ark-invest-foresees-crypto-industry-boost-under-incoming-trump-administration">White House administration</a>.</p>
<p>Wood has shared price targets for Bitcoin over the years, including a high of $3.8 million for BTC by the year 2030. Here's a look at how much a small investment in Bitcoin today could increase over time if Wood's various price targets are reached in the future.</p>
<p><strong>Following Wood Into Bitcoin: </strong>With Bitcoin<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41778425/bitcoins-all-time-high-a-groundbreaking-milestone-and-strong-post-election-rally-coming-ex"> hitting all-time highs </a>after the 2024 presidential election, big questions remain about how high the leading cryptocurrency can go and how long it will take to reach various milestones like $100,000.</p>
<p>Earlier this year, Wood laid out <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/02/30660447/cathie-woods-ark-sees-bitcoin-joining-trillion-dollar-club-by-2030-here-are-its-bea">her price targets </a>for Bitcoin based on a bear case, base case and bull case for the year 2030. Wood also added a new bull case that includes the potential highest price Bitcoin <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37902973/cathie-wood-says-bitcoin-could-skyrocket-to-3-8m-by-2030-thanks-to-institutional-gr">could reach by 2030</a> if companies allocated 5% to Bitcoin.</p>
<p>With Bitcoin trading at $89,384.76 at the time of writing, an investor could buy 0.00112 BTC today with $100. Here is a look at how much that $100 would be worth in the future under Wood's various price targets.</p>
<ul>
<li>Bear Case, $258,500: $100 today would be worth $289.52, up 189.5%</li>
<li>Base Case, $682,000: $100 today would be worth $763.84, up 663.8%</li>
<li>Bull Case, $1,480,000: $100 today would be worth $1,657.60, up 1,557.6%</li>
<li>Bullish Case, $3,800,000: $100 today would be worth $4,256.00, up 4,156.0%</li>
</ul>
<p>As you can see, a small investment would turn into a sizable return if Wood&#8217;s base or bullish predictions come true. Even the bearish price target hitting would more than double the investment from today.</p>
<p>While there&#8217;s no guarantee that any of the price targets will hit, the exercise shows how a small investment in cryptocurrency could add up over time.</p>
<p>Read Also: <strong><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">EXCLUSIVE: Why Does Cathie Wood Think Bitcoin Is Going To $1 Million — What Does She Know That We Don&#8217;t?</a></strong></p>
<p><strong>What's Next: </strong>Wood recently reiterated her price targets in a CNBC <a href="https://x.com/BitcoinMagazine/status/1857483221857865879">interview </a>while highlighting how Ark Invest was early to investing in Bitcoin.</p>
<p>"We were the first public asset manager to gain exposure to Bitcoin in 2015 at $250," Wood said.</p>
<p>Wood said that even with Bitcoin trading around $90,000, the company believes there is a long way to go.</p>
<p>The fund manager said that getting regulatory relief with a new administration is one of the most important things for Bitcoin. Wood also sees Bitcoin being viewed as a new asset class, leading to more institutions and asset allocators wanting to invest in the top cryptocurrency.</p>
<p>Wood&#8217;s Ark Invest <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36605838/ark-invest-ceo-cathie-wood-projects-a-single-bitcoin-could-be-worth-1-5m-by-2020-probabili" target="_blank" rel="noreferrer noopener">was also one of several companies&nbsp;</a>to have a Bitcoin ETF approved by the SEC with its&nbsp;<strong>Ark 21 Shares Bitcoin ETF&nbsp;</strong>(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>).</p>
<p>Wood's most recent $3.8 million price target might be one of the biggest from a fund manager and among the most bullish bets on cryptocurrency. The target came from the approval and early success of Bitcoin ETFs earlier this year.</p>
<p>&#8220;With this institutional green light that the SEC has provided, kicking and screaming though it did, the analysis we&#8217;ve done is that if institutional investors were to allocate a little more than 5% of their portfolios to bitcoin, as we think they will over time, that alone would add $2.3 million to the projection I just gave you,&#8221; Wood said.</p>
<p>Adding $2.3 million to the $1.5 million leads to a new price target of $3.8 million for 2030.</p>
<p>The approval of<a href="https://www.benzinga.com/topic/bitcoin-etf" target="_blank" rel="noreferrer noopener"> the Bitcoin ETFs </a>led Wood to say in an interview that &#8220;the probability of the bull case has increased.&#8221;</p>
<p>Wood and Ark Invest aren't just betting on the success of Bitcoin with its cryptocurrency holdings and the ETF, the company is also investing in crypto-related companies.</p>
<p>The flagship<strong> Ark Innovation ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) <span style="box-sizing: border-box; margin: 0px; padding: 0px;"><a href="https://www.ark-funds.com/funds/arkk" target="_blank" rel="noopener">has </a><strong>Coinbase Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) as its third-largest holding, accounting for 9.5% of its assets. <strong>Robinhood Markets </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) is the fund's sixth-largest holding, accounting for 5.0% of its </span>assets.</p>
<p>Bitcoin hit an all-time high of $93,434.36 on Nov. 13, one of several records set after the 2024 election.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41951961/bitcoin-to-100k-benzinga-readers-predict-if-btc-can-hit-new-milestone-before-end-of-2024">Bitcoin To $100K? Benzinga Readers Predict If BTC Can Hit New Milestone Before End Of 2024</a></strong></li>
</ul>
<p><em>This article was previously published by Benzinga and has been updated.</em></p>
<p><em>Image created using a photos courtesy of Ark Invest and Shutterstock.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Education

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

ARKK

COIN

HOOD

Here's How Much $100 In Bitcoin Could Be Worth In 2030 If Cathie Wood's Price Target Is Reached

<p>President-elect <strong>Donald Trump</strong> has announced that <strong>Robert F. Kennedy Jr. (RFK Jr.)</strong> will serve as the <strong>Secretary of Health and Human Services (HHS).</strong> Trump described Kennedy's mission as one to address the "industrial food complex" and pharmaceutical companies, which he accused of spreading "misinformation and disinformation."</p>
<p>In his announcement, Trump emphasized that Kennedy's leadership would "restore these agencies to the traditions of gold standard scientific research and beacons of transparency to end the chronic disease epidemic." He also noted that the safety and health of Americans would remain a central focus of the new administration.</p>
<p>Earlier <a href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics">remarks</a> by Trump indicated that Kennedy would be given significant freedom in his role, with the president-elect stating that he would allow Kennedy to "go wild on health" to address systemic issues in the country's healthcare system. While the specific implications of this statement remain unclear, it reflects Trump's confidence in Kennedy's ability to tackle what he views are broad public health challenges.</p>
<h3 class="wp-block-heading"><strong>Polarizing Appointment With Major Implications</strong></h3>
<p>Kennedy's appointment has drawn attention due to his well-documented skepticism about vaccine safety, including his past promotion of <a href="https://www.chop.edu/vaccine-education-center/vaccine-safety/vaccines-and-other-conditions/autism">debunked theories linking vaccines to autism</a>, claims widely rejected by the scientific community. This history raises questions about how RFK&#8217;s leadership will influence key public health initiatives.</p>
<p>Despite this background, Kennedy's policy positions on <a href="https://www.benzinga.com/cannabis">cannabis and psychedelics</a> suggest he could drive significant reforms in these areas. His advocacy for these substances has gained traction as public opinion shifts and bipartisan support grows for drug policy reform.</p>
<h3 class="wp-block-heading"><strong>Kennedy's Cannabis Policy Vision</strong></h3>
<p>As HHS Secretary, Kennedy's approach to cannabis will likely be closely scrutinized. He has consistently advocated for federal decriminalization, envisioning a framework where states can regulate cannabis while the federal government collects tax revenue to fund rehabilitation centers. These centers, which RFK has proposed establishing in rural areas, would emphasize holistic recovery practices, such as gardening and forestry.</p>
<p>Kennedy's broader public health goals align with this vision. He has pushed for reducing barriers to entry for cannabis businesses while addressing addiction and recovery challenges nationwide. A significant element of his policy is enabling safe banking for cannabis businesses. He has called for reforms to end the industry's reliance on cash transactions, which pose security risks and limit financial access.</p>
<h3 class="wp-block-heading"><strong>Psychedelics: A Personal And Policy Frontier</strong></h3>
<p>Kennedy's advocacy for psychedelics stems from both personal experiences and the growing body of research on their potential mental health benefits. He has shared how his son's use of ayahuasca helped him process grief, an experience that informed Kennedy's cautious but supportive stance on psychedelics.</p>
<p>"My inclination would be to make them available, at least in therapeutic settings and maybe more generally, but in ways that would discourage corporate control and exploitation," Kennedy <a href="https://www.benzinga.com/markets/cannabis/23/12/36289732/psychedelics-legalization-2024-election-robert-f-kennedy-jr-confirms-support-in-new-interview">said in an interview</a> with Genius Network in 2023. His perspective suggests a focus on accessibility while resisting the commercialization of these substances, aiming to prioritize therapeutic applications.</p>
<h3 class="wp-block-heading"><strong>What's Next For Reform?</strong></h3>
<p>Kennedy's confirmation as HHS Secretary has sparked discussion about how his views will shape drug policy in the U.S. His positions on cannabis decriminalization, safe banking reforms and therapeutic uses of psychedelics align with increasing public and political support for change. However, his history of promoting discredited vaccine theories and his polarizing reputation could complicate efforts to build consensus within the administration and among public health stakeholders.</p>
<p>While the specifics of Kennedy's role are still emerging, his appointment signals a potential pivot in federal approaches to cannabis and psychedelics. Industry stakeholders, from advocates to investors, will be watching closely to see whether his leadership results in meaningful reform.</p>
<p><em>This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Photo: Shutterstock</em></p>


Cannabis

Government

Health Care

Trump's 'Go Wild On Health' Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform

<p><strong>Shares of Moderna Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) are trading lower after President-elect <strong>Donald Trump</strong> nominated <strong>Robert F. Kennedy Jr. </strong>to lead the Department of Health and Human Services. Here&#8217;s <a href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous">what you need to know.</a></p>
<p><strong>What To Know: </strong>Kennedy has been a vocal critic of vaccines and mainstream medical practices, raising concerns about potential reforms at federal health agencies, including the FDA and NIH. Speculation about reduced funding, department eliminations and restructuring at the NIH has created unease among employees and investors. FDA staff are reportedly considering resignations due to concerns about Kennedy's potential policies. </p>
<p>Kennedy has proposed reducing the NIH's 27 divisions to 15 and replacing 600 employees, raising alarms about the future of federally funded research and its independence. Employees at the FDA and NIH are apprehensive about potential budget cuts and the politicization of research. For Moderna, this creates uncertainty about the future of vaccine development and approval processes.</p>
<p>Industry representatives, including the Pharmaceutical Research and Manufacturers of America, have expressed concerns about preserving innovation and maintaining the U.S.'s leadership in drug development. Despite the uncertainty, they indicated they may collaborate with the incoming administration to address healthcare challenges.</p>
<p><strong>Why It Matters:</strong> These developments have heightened investor fears about the pharmaceutical sector, particularly vaccine developers like Moderna, which rely on federal approval processes and public trust in immunization programs.</p>
<p>The uncertainty surrounding federal health policies and their impact on vaccine programs is driving the sell-off in Moderna and other vaccine stocks. Shares are under pressure as investors weigh the potential for reduced government support and a more challenging regulatory environment.</p>
<p><strong>MRNA Price Action:</strong> Moderna shares were down by 6.16% at $37.33 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="546" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15141051/MRNA-1024x546.png" alt="" class="wp-image-651056" style="width:543px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15141051/MRNA-1024x546.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15141051/MRNA-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15141051/MRNA-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15141051/MRNA.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42016220/ai-meme-coin-goat-joins-1-billion-club-can-it-target-the-likes-of-dogecoin-shiba-inu">AI Meme Coin GOAT Joins $1 Billion Club—Can It Target The Likes Of Dogecoin, Shiba Inu?</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Movers

MRNA

Moderna Shares Are Dipping Today: What's Going On?

<p><strong>Microsoft Corp.&#8217;</strong>s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Blizzard Entertainment has dropped a significant hint regarding an upcoming project that could redefine the future of the <a href="https://www.benzinga.com/general/gaming">StarCraft franchise. </a></p>
<p><a href="https://www.ign.com/articles/blizzard-job-ad-confirms-upcoming-open-world-shooter-is-in-the-works-and-all-signs-point-to-starcraft">According</a> to IGN, a job listing posted on Nov. 13 reveals Blizzard is seeking an &#8220;associate design director, innovation,&#8221; for an &#8220;upcoming open-world shooter game,&#8221; and all signs point to this being the long-anticipated StarCraft FPS.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/general/gaming/24/11/42013601/phil-spencer-responds-to-this-is-an-xbox-criticism-were-in-the-middle-of-a-transition">Phil Spencer Responds To &#8216;This Is An Xbox&#8217; Criticism: &#8216;We&#8217;re In The Middle Of A Transition&#8217;</a></strong></p>
<p>The job ad promises that the chosen candidate will &#8220;be the vision holder and owner of key strategic innovations&#8221; for the project, with focus on both indie and AAA developments.</p>
<p>Blizzard is looking for a candidate who is not only capable of overseeing innovative game mechanics but also someone who can transform &#8220;dreams into reality that players can get their hands on and enjoy.&#8221;</p>
<h1 class="wp-block-heading"><strong>A StarCraft FPS In Development?</strong></h1>
<p>The job listing comes on the heels of reports earlier this year that Blizzard was actively working on a StarCraft first-person shooter. </p>
<p>These reports traced back to a September revelation by Bloomberg reporter <strong>Jason Schreier</strong> during an appearance on IGN's Podcast Unlocked. Schreier, who is no stranger to inside knowledge at Blizzard, shared that <a href="https://www.benzinga.com/general/gaming/24/09/41074461/blizzards-history-with-starcraft-shooters-is-not-good-will-third-attempt-succeed">the company was attempting a third shot at creating a StarCraft shooter</a>, with former Far Cry executive producer <strong>Dan Hay </strong>leading the charge.</p>
<p>"I have heard that they are working on a StarCraft shooter," Schreier said at the time. "StarCraft is not dead at Blizzard.&#8221;</p>
<p>However, the journalist also noted that Blizzard&#8217;s history with StarCraft shooters has been anything but smooth. This has been a long-running saga, marked by the company's failed attempts to expand the franchise beyond its real-time strategy roots.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41952020/76-of-children-plan-to-ask-for-video-games-this-christmas-survey-shows">76% Of Children Plan To Ask For Video Games This Christmas, Survey Shows</a></li>
</ul>
<p><em>Photo: Shutterstock.</em></p>


Gaming

MSFT

A New StarCraft FPS? Blizzard's Latest Job Posting Hints At Huge Project

<p><strong>Netflix Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is leveraging tonight&#8217;s boxing match between <strong>Mike Tyson</strong> and <strong>Jake Paul</strong> to <a href="https://www.benzinga.com/topic/streaming">bolster its live offerings</a>. </p>
<p>The streaming service, which has been <a href="https://www.benzinga.com/general/sports/24/11/41985523/paul-vs-tyson-boxing-match-how-to-watch-betting-odds-what-the-stats-say-and-more">pushing into live sports content</a>, currently boasts more than 282 million global paid subscribers. Its ad-supported plan recently hit <a href="https://www.benzinga.com/media/24/11/41915397/netflix-reaches-70-million-users-on-ad-supported-plan-boosts-live-sports-ads">70 million subscribers</a>.</p>
<p>So far, Netflix has aired live comedy stand-ups, award shows, roasts and other special events. This is its inaugural boxing event.</p>
<p>Taking place at <strong>AT&amp;T Stadium</strong> in Dallas, the fight features a dramatic age gap. Tyson, 58, is a boxing legend known for his fierce power. His career record is 50 wins and six losses. Paul, 27, is a social media personality turned boxer beginning in 2020. He holds a 10-1 record with seven knockouts in his career. His lone loss came via a split decision to <strong>Tommy Fury</strong> in February 2023.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41985133/mike-tyson-on-psychedelics-the-toad-showed-me-god-and-it-changed-my-life">Mike Tyson On Psychedelics: &#8216;The Toad Showed Me God, And It Changed My Life&#8217;</a></strong></p>
<p>Tyson's last professional fight was in 2005, although he participated in a high-profile exhibition match in 2020 against Roy Jones Jr., which ended in a split draw. </p>
<p>The buildup took an ugly turn when, during the weigh-in, Tyson slapped Paul. </p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Mike Tyson Slaps Jake Paul During Their Weigh-In" width="500" height="281" src="https://www.youtube.com/embed/7ImTO88zN-s?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p>This real, officially sanctioned fight will be a significant test for both fighters, adding excitement to the streaming giant's growing sports portfolio.</p>
<p><strong>Astronomical</strong> <strong>Cost To Attend:</strong> The celebrity fight promises huge profits. Per a <a href="http://Per a report by USA Today,">report</a> by USA Today, with 80,000 seats and VIP packages ranging from $5,000 to $25,000, the event is set to generate millions.</p>
<p>The exclusive MVP Owner&#8217;s Experience is valued at $2 million, and the fight will also stream live on Netflix, which will benefit from a significant audience. </p>
<p>Tyson is estimated to earn $20 million, while Paul aims for $40 million.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41235640/netflix-to-become-default-choice-for-tv-movies-analyst-predicts-more-live-sports-pr">Netflix To Become &#8216;Default Choice&#8217; For TV, Movies? Analyst Predicts More Live Sports, Price Increases</a></strong></p>
<p><strong>Betting Big:</strong> Per a <a href="https://nypost.com/2024/11/14/betting/jake-paul-bets-40-million-purse-that-hell-beat-mike-tyson/">report</a> by the NY Post, Paul has taken his confidence to the extreme, betting his entire $40 million purse on himself for his upcoming fight against Tyson.</p>
<p>During a pre-fight exchange, Paul accepted a challenge from Irish boxer <strong>Katie Taylor</strong> to wager his earnings, with Tyson favored to win.</p>
<p>While unlikely to see the bet come to fruition, Taylor, set to earn $6.1 million for her own fight against <strong>Amanda Serrano</strong>, stands at +650 odds for Tyson's victory.</p>
<p>In a bold move, <a href="https://www.vox.com/culture/385235/jake-paul-mike-tyson-fight-netflix">Paul offered Tyson $5 million</a> if he can last beyond four rounds. However, if Tyson fails, he must get a tattoo reading "I love Jake Paul." </p>
<p>Tyson responded with his own counteroffer, demanding $20 million to agree to the challenge. This bet adds to the spectacle, further heightening the tension between the two fighters. It also fuels interest in the already highly anticipated event, blending high stakes with controversy.</p>
<p><strong>Read Also: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/11/41945418/netflix-stock-hit-a-new-all-time-high-whats-going-on">Netflix Stock Hit A New All-Time High: What&#8217;s Going On?</a></strong></li>
</ul>
<p><em>Image: Netflix</em></p>


Entertainment

Sports Betting

Sports

NFLX

Netflix Streams Mike Tyson Vs. Jake Paul: The Fight Everyone's Talking About

Rumors

Trading Ideas

CELH

Watching Shares Of Celsius; Co. M&A Blog Mentioning The Company As A Potential Target For An Activist Investor

WIIM

JNPR

Juniper Networks shares are trading lower amid reports suggesting the DOJ is examining depositions of the company and Hewlett Packard Enterprise's executives and third-party CID responses.

<p>The dust is beginning to settle from the 2024 election, and companies are starting to digest what a second Trump term means for business. On the campaign trail, Candidate Trump promised another round of tariffs on foreign goods, but it remains to be seen what promises actually translate into law once the administration comes to power.&nbsp;</p>
<p>Some companies like Steve Madden are attempting to get ahead of the curve by <a href="https://www.benzinga.com/24/11/41862692/steve-madden-announces-plans-to-move-production-to-avoid-trump-tariffs-but-theres-a-catch">moving production out of China now</a>, but others aren't as nimble and will likely bear the brunt of higher costs. Which public companies are likely to be hit hardest by tariff expansion? Here&#8217;s a list of 4 stocks you might want to consider selling before the next trade war salvo.</p>
<h2 class="wp-block-heading">Methodology</h2>
<p>Each company chosen for this list faces at least one of the following issues:</p>
<ul>
<li>Reliance on imports, especially goods from China </li>
<li>Limited ability to pass higher costs onto customers </li>
<li>Lack of negotiating power with suppliers&nbsp;</li>
<li>Thin margins that could make it challenging to absorb costs </li>
</ul>
<p>The retail industry is already bracing for higher costs. According to the National Retail Foundation, companies are preparing for these additional costs by raising prices on a variety of goods that could cost consumers between $46 billion and $76 billion in purchasing power. Retail will be a major theme amongst these stock picks, especially in areas where customers expect low prices and have substantial alternatives.</p>
<h3 class="wp-block-heading">Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</h3>
<p>Dell has been one of the market's biggest winners since the start of 2023. The company has re-entered the S&amp;P 500 and its stock price has soared from under $40 in March 2023 to over $130 as of this writing. The stock has pulled back a bit since hitting an all-time high of $179 in May, and more pain could be on the way if the proposed tariffs come to be.</p>
<p>Dell sells a variety of electronics, from computers and laptops to cloud and networking solutions. This line of electronics depends on affordable printed circuit boards (PCBs), capacitors, resistors, casings, and assembly operations, and much of this company infrastructure is located in China. Additional tariffs on these components could force Dell to either raise prices faster than customers see reasonable or relocate some of their production outside of China. Either solution could hamper future stock growth. Dell is currently rated a Buy, but the <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">most recent analyst reports</a> put the consensus price target at $117, which is below the current market price.</p>
<h3 class="wp-block-heading">Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)</h3>
<p>If you or your spouse are primary education teachers, you likely have spent a lot of time in Five Below looking for school supplies, affordable electronics, student rewards, and perhaps some candy for the lounge. The company sells a variety of merchandise at highly discounted prices, and many of its electronic products are imported from China.</p>
<p>Five Below gets hit from both sides in a potential tariff war. Not only is the company heavily reliant on Chinese imports, but its business model leaves very little room to raise prices. Customers who see higher prices at specialty retailers like Five Below may just take their business to higher-end competitors like Target Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>). Analysts currently rate FIVE stock as a Hold with an average price target of $129. However, the three most recent analyst reports (Truist, BofA Securities, and Evercore ISI) only had an average price target of $89, which is about where shares are currently trading. BofA analyst Lorraine Hutchinson <a href="https://www.cnbc.com/2024/11/06/trump-proposed-tariffs-consumer-prices.html">noted in her downgrade</a> that Five Below sources more than 20% of its products from China and lacks the pricing power to pass those costs onto consumers.</p>
<h3 class="wp-block-heading">Lowe's Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>)</h3>
<p>Another big winner from the past two years could be facing more headwinds if tariffs come to fruition. Lowe's has benefited from the home price boom as millions of Americans tapped their expanding home equity for upgrades and renovations following COVID. LOW shares shot from a pandemic low of $86 to $258 by December 2021 and recently made a new all-time high at $270 a few weeks ago. However, if we use history as a guide, Lowe's stock had a choppy ride during the first round of tariffs in 2017.</p>
<p>Lowe's sells high-end appliances like washing machines, dryers, refrigerators, water heaters, and other important (and imported) home goods. Not only will the company face higher costs on these expensive goods, but consumers who have already tapped chunks of home equity may put off new projects or rush to buy before the tariffs kick in. From 2017 to 2020, LOW shares exhibited high volatility with four different 15% corrections. With more tariffs on tap and consumers stretched thin, Lowe's profits could take a hit in the coming months. The company reports earnings on November 19 and investors will be looking for clues on how tariffs could affect its bottom line.</p>
<h3 class="wp-block-heading">Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</h3>
<p>Another stock up big this year, and another company under pressure from the incoming administration. Walmart didn't suffer as much as the broader indices during the 2022 bear market, but the stock has roared to life in 2024. WMT shares are up over 60% year-to-date, including an eye-popping 41% in the last six months. The company has beaten analyst earnings expectations in each of the previous eight quarters as well.</p>
<p>In recent years, Walmart has sought to divest itself from China by moving some production to India, but Chinese imports still make up <a href="https://www.reuters.com/business/retail-consumer/walmart-shifts-india-china-cheaper-imports-2023-11-29/">about 60%</a> of the company's products. It's unlikely that much more production will be moved out of China by the time tariffs take effect, and Walmart doesn't have the supplier negotiating power that a company like Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) does. Additionally, Walmart's Every Day Low Price model runs on razor-thin margins. In July, Walmart reported a <a href="https://www.macrotrends.net/stocks/charts/WMT/walmart/net-profit-margin">net profit margin of 2.34%</a>. While not as low as some previous reports, Walmart has consistently seen its net margin drop below 3% since the first Trump administration, and the company may not have the pricing power to pass additional tariff costs onto its customers.</p>
<p>Take the guesswork out of investing with a handpicked portfolio of value stocks that consistently outperforms the S&amp;P 500. Invest in a proven, time-tested selection designed for long-term growth. <strong><a href="https://www.benzinga.com/premium/ideas/perfect-portfolio/?utm_source=RD-1115">Click to get access now.</a></strong></p>
<p>Image via Shutterstock</p>


Opinion

COST

DELL

FIVE

4 Stocks to Sell Before Trump's Tariffs Take Effect

<p>Needham  analyst Laura Martin   maintains Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) with a Buy and raises the price target from $8.5 to $9.5.</p>


Price Target

Needham Maintains Buy on Nexxen International, Raises Price Target to $9.5

BurTech Acquisition Corp. Class A (BRKH) has shared an announcement. BurTech Acquisition Corp. has received a notice from Nasdaq due to non-complia...

Comments

BurTech Acquisition

空売り

BurTech Acquisition (NASDAQ:BRKH) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル